LOX1, His, Mouse
LOX1, His, Mouse

The purity of LOX1, His, Mouse is greater than 95% as determined by SEC-HPLC.

LOX1, His, Mouse

LOX1, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LOX1, His, Mouse

LOX-1 is a transmembrane glycoprotein that binds to and internalizes ox-LDL.LOX-1 gene deletion in mice and anti-LOX-1 therapy has been shown to decrease inflammation, oxidative stress and atherosclerosis. LOX-1 deletion also results in damage from ischemia, making LOX-1 a promising target of therapy for atherosclerosis and related disorders. In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis.
Z06245
¥63,425.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
His LOX1 (Arg60-Ile363)_x000D_
Accession # Q9EQ09
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 36.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-63 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • LOX1, His, Mouse
    • LOX1, His, Mouse

    The purity of LOX1, His, Mouse is greater than 95% as determined by SEC-HPLC.

  • LOX1, His, Mouse
    • LOX1, His, Mouse

    LOX1, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background LOX-1 is a transmembrane glycoprotein that binds to and internalizes ox-LDL.LOX-1 gene deletion in mice and anti-LOX-1 therapy has been shown to decrease inflammation, oxidative stress and atherosclerosis. LOX-1 deletion also results in damage from ischemia, making LOX-1 a promising target of therapy for atherosclerosis and related disorders. In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis.
Synonyms Ox-LDL receptor 1; LOX-1; CLEC8A; LOX1; OLR1; LOXIN; SR-E1; SCARE1; SLOX1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.